Our Clients
CeeTox’s proprietary in Vitro screens are utilized by bio/pharmaceutical, chemical, nutraceutical and government entitities, and continually demonstrates the value of its technology to their clients’ discovery efforts.
Cytorex Biosciences, Inc.
Weston, Florida
CeeTox had an opportunity to work with Cytorex’s proprietary compound Cytoreg®, a great innovation in the fight against cancer. The testing performed by CeeTox, in rat hepatoma (liver cancer), normal hepatocytes (liver), and normal kidney cells, indicated a distinctive cytotoxic activity of Cytoreg® in cancer cells. The CeeTox results were included in the preclinical data package evaluated by the National Cancer Institute, and allowed Cytorex to reach a collaboration agreement with the NCI, to develop the Cytoreg® program as a potential treatment for glioblastoma multiforme (brain cancer).
Vertex Pharmaceuticals, Inc.
Cambridge, Massachusetts
“We began collaborating with CeeTox in 2006. Incorporating CeeTox’s technology into our drug discovery efforts is helping us to select the best compounds for clinical testing from our discovery efforts, as well as select initial doses for evaluation in clinical trials.”
Technology Manager, Program Management and Strategic Planning, Vertex Pharmaceuticals, Inc.
Alliances/Collaborations
CeeTox works closely with scientists and technology partners to advance new chemical entities for the drug development market.
ADMETRx
Kalamazoo, Michigan
A Kalamazoo-based company providing in vitro ADME discovery support. Given the critical integration of toxicity screening and ADME testing in drug discovery, lead selection and optimization, particularly in the assessment of potential drug-drug interactions and idiosyncratic toxicities, this alliance provides the pharmaceutical and biotech customers with maximum efficiencies, that will improve the effectiveness of discovery decision-making.
Biotrin
Dublin, Ireland
Headquartered in Dublin, Ireland, CeeTox collaborates with Biotrin’s Biomarkers Unit, which includes a range of novel, proprietary biomarkers to assess organ and tissue damage.